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MouseMyostatin is a TGFb family ligand that reduces muscle mass. In cancer cells, TGFb signalling is
increased by the protein FHL1. Consequently, FHL1 may promote signalling by myostatin. We there-
fore tested the ability of FHL1 to regulate myostatin function. FHL1 increased the myostatin activity
on a SMAD reporter and increased myostatin dependent myotube wasting. In mice, independent
expression of myostatin reduced fibre diameter whereas FHL1 increased fibre diameter, both consis-
tent with previously identified effects of these proteins. However, co-expression of FHL1 and myo-
statin reduced fibre diameter to a greater extent than myostatin alone. Together, these data suggest
that the expression of FHL1 may exacerbate muscle wasting under the appropriate conditions.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Voluntary movement is essential for a normal healthy life and
the performance of daily activities. Such movement requires a suf-
ficient quantity of skeletal muscle especially in the locomotor mus-
cles and the appropriate proportions of the different fibre types.
Different fibre-types have distinct rates of contraction and abilities
to endure activity. The overall phenotype of a muscle is related to
the relative proportions of the different fibres it contains. Muscle
phenotype is plastic and the size and proportion of the individual
fibres can change dependent on a number of factors including
physical activity.
Changes in muscle mass and phenotype are important aspects
of a number of chronic diseases such as chronic obstructive pul-
monary disease (COPD), heart failure and cancer and have prognos-
tic ability. Indeed exercise capacity and strength are better
predictors of survival in patients with COPD than standard mea-
sures of pulmonary function [1]. Muscle mass is also lost in ageing
and there is a marked change in phenotype again with prognosticimplications [2,3]. Consequently the factors that affect muscle
mass are being intensively studied.
Not all fibres atrophy at the same rate and a number of studies
have shown that type II fibres are more likely to atrophy than type
I fibres in diseases as varied as COPD [4], heart failure [5] and
osteoarthritis [6] as well as in normal human ageing [7]. As there
is a shift towards type II fibres in the quadriceps muscles in chronic
disease, this increased sensitivity of type II fibres to atrophy is
likely to contribute to accelerated wasting. Under some conditions
(e.g. starvation) where muscle acts as an emergency fuel store, this
response may be important; however, in chronic disease it is likely
to be detrimental.
Myostatin is one factor likely to be involved in the increased
susceptibility of type II fibres to atrophy. This growth regulator is
a member of the transforming growth factor-b (TGF-b) family that
was identified from natural mutations in animals with a double
muscled phenotype [8,9]. Germ-line deletion of the myostatin gene
from mice resulted in a similar hypermuscular phenotype suggest-
ing that myostatin is an inhibitor of muscle growth. Deletion of
myostatin also increased the proportion of the fastest type IIB
fibres suggesting that the major effects of myostatin were on this
fibre type [10,11]. Furthermore myostatin expression is highest
in type IIB fibres [12], is elevated in response to hind limb suspen-
sion and is a target for the type I fibre restricted microRNA, miR-
499. Indeed it has been shown that increased myostatin mRNA
and protein are associated with type II muscle atrophy [13].
Fig. 1. Effect of FHL1 on TGF-b ligand induced signalling. C2C12 myoblasts were
transfected with a SMAD responsive luciferase reporter in the presence and absence
of FHL1. Subsequently, cells were treated with either TGF-b (10 ng/mL) or
myostatin at 20, 50 and 100 ng/mL. FHL1 caused a large potentiation of TGF-b
induced p(CAGA)12 activity (A). Myostatin caused a small increase in p(CAGA)12
activity at 100 ng/mL. However, FHL1 enhanced p(CAGA)12 activity at 20 ng/mL
myostatin and above (B). Data represents 4 independent experiments performed in
triplicate normalised to untreated pCDNA control. #p < 0.05, ##p < 0.01,
###p < 0.001. Compared to no myostatin for the same transfection, and ⁄⁄p < 0.01
FHL1 compared to control for the same myostatin concentration.
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complex promoting the phosphorylation of SMAD-2/3. Conse-
quently factors that modify SMAD-2/3 phosphorylation are likely
to alter myostatin signalling. One protein that activates SMAD pro-
teins is the four and a half LIM domain protein FHL1 which binds to
CKd and promotes SMAD phosphorylation [14]. In muscle cells
such an activity would promote muscle atrophy but under normal
conditions FHL1 appears to promote hypertrophy. For example,
over-expression of FHL1 leads to muscle hypertrophy [15] and
patients with mutations in FHL1 have a range of myopathic condi-
tions including X-linked myopathy with postural muscle atrophy
(XMPMA) [16]. However, a number of studies have shown that
FHL1 can associate with atrophy. For example, denervation in mice
increases FHLI [17], long-term training in humans reduces FHL1expression [18] and we observed that FHL1 was associated with
weakness in COPD patients [19]. These observations raise the pos-
sibility FHL1 potentiates myostatin signalling in muscle cells so
contributes to muscle wasting under a subset of conditions. Conse-
quently in this study we determined the effect of FHL1 on SMAD
reporter gene expression in response to myostatin, as well as the
effect of FHL1 on myostatin induced myotube wasting. Finally we
used electroporation of the tibialis anterior (TA) in mice to deter-
mine the effect of FHL1 on myostatin induced muscle wasting
in vivo.
2. Materials and methods
2.1. Cloning
Full-length murine myostatin and FHL1 were sub-cloned into
pGEMT by PCR from image clones (Source Bioscience) then shut-
tled into empty pCAGGS expression vector (containing a CMV-
enhancer and chicken b-actin promoter) [20] and sequenced.
Large-scale plasmid preparations were carried out using the Endo-
Free Mega kit (Qiagen) according to manufacturer’s instructions
and plasmids were eluted in sterile dH20.
2.2. Cell culture, luciferase reporter and myotube diameter assays
For luciferase experiments, C2C12 myoblasts were cultured and
transfected using lipofectamine as described in [21] scaled for cul-
ture in 24 well plates. A total of 0.4 lg DNA was transfected per
well in total: 0.2 lg of (CAGA)12-luciferase plasmid [22], 0.1 lg of
pRLTK plasmid, 0.1 lg of either FHL1-pcDNA or 0.1 lg pcDNA as
the control. After transfection the cells were cultured in DMEM
supplemented with 10% (v/v) FBS. Twenty-four hours later, cells
were serum starved for 7 h then washed and treated with serum-
free DMEM containing either TGF-b1 (Insight Biotechnology) or
Myostatin (PromoKine) for 16 h. Luciferase activity was assayed
using the Dual-Luciferase Reporter Assay System (Promega)
according to the manufacturer’s instructions. Firefly luciferase
activity was normalised to Renilla luciferase activity to account
for transfection efficiency. All data were normalised to the mean
of the pcDNA untreated (0 ng/mL TGF-b) group for that set of
transfections.
For myotube diameter measurements, C2C12 myoblasts were
cultured and transfected as described in [23] with a total of 2 lg
DNA consisting of 0.5 lg pCAGGS-GFP [24]and either 1.5 lg
FHL1-pcDNA or 1.5 lg pcDNA. Thus, myoblasts that were success-
fully transfected with pCAGGS-GFP would also be transfected with
the FHL1 expression vector and allow identification of fluorescent
‘transfected’ myotubes. After 4.5 h incubation, media was replaced
with fresh DMEM + 10% FBS and the cells returned to the incuba-
tor. The medium was replaced every 2 days and allowed to become
confluent (approximately 3 days). The media was replaced with
DMEM supplemented with 2% horse serum (differentiation med-
ium) to differentiate myoblasts into myotubes for 7 days, with
fresh replacement every 2 days. Myotube formation was confirmed
by the presence of multinucleate cells and parallel experiments
looking at the expression of myogenic regulatory factors and MHCs
showed an increase in the expression of all MHCs with an increase
in myogenin expression consistent with previous observations
[25,26] (data not shown). After 7 days, the media was then
replaced with differentiation medium supplemented with 20 ng/
mL myostatin (PromoKine) or vehicle control (0.1% BSA and
20 mM HCl). After 48 and 96 h of exposure, fluorescent myotubes
were identified in randomly selected views at 10 magnification
and captured using a Hamamatsu C4742-95-12ERG camera
attached to a Zeiss Axiovert 200 microscope with the filter set
Fig. 2. FHL1 enhances myostatin induced wasting in C2C12 myotubes. C2C12 myoblasts were co-transfected with an EGFP expression vector (pCAGGS-EGFP) and either
pCDNA or pCAGGS-FHL1 and differentiated into myotubes before treatment with myostatin for 4 days. FHL1 expression induced myotube hypertrophy. At 20 ng/mL,
myostatin alone had no effect on myotube diameter, however, in the presence of FHL1, myostatin reduced myotube diameter. Representative images of each group at day 2
are shown in (A) with fluorescent images alone on the top row and merged with the brightfield images below. Quantitation of myotube diameters after 2 (B) and 4 (C) days of
treatment. Images captured at 10 magnification, scale bar represents 120 lm. Graphs represent median ± IQR of pooled data from 3 independent experiments (⁄p < 0.05 and
⁄⁄⁄p < 0.001 Mann Whitney).
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measuring the shortest distance across the myotube at five points
along the length of fluorescent myotubes using Image J.
2.3. Electroporation
Mouse experiments were approved by the Royal Veterinary Col-
lege Ethical Review Process (ERP-A-2010-WS01) and were licensed
by the UK Secretary of State for the Home Office under Project
License PPL 70/6797. Twelve female CD1 mice (7.5 weeks old)
were anaesthetised with Hypnorm (VetaPharma) and Hypnovel
(Roche), both lower legs were shaved and 10U (25 ll) of bovine
hyaluronidase (Sigma) was injected percutaneously into each TA
to increase transfection efficiency [27,28]. Mice were allowed to
partially recover at 37 C and after 1.5 h they were re-
anaesthetised using 5% isofluorane and maintained at 2% isofluo-
rane. The TA muscles were injected with 25 ll of the appropriate
plasmid at 1 mg/mL. Immediately following the plasmid injection
electro-conductive cream was applied to electrodes which were
placed either side of TA, separated by approximately 5 mm. Elec-
troporation was performed using 10 pulses of 85 V each for
20 ms, at a frequency of 1 Hz.
Following electroporation, mice recovered and were left for
2 weeks, after which the mice were sacrificed and TA muscles were
harvested and placed upright onto small pieces of cork with a small
amount of OCT at the bottom to fix the bottom of the TAs onto cork
and flash frozen in liquid nitrogen cooled iso-pentane.Muscle samples were sectioned as previously described [27] to
obtain tissue for histology and RNA analysis from defined levels
within the muscle. Muscle sections were stained with haema-
toxylin and eosin, and by immunofluorescence for fibre type as
previously described [29]. Random fields were captured at 20
magnification using an Olympus CKX41 camera and Cell^D soft-
ware (Olympus Europe).
2.4. RNA extraction from tissue
Muscle sections from regions adjacent to the histology samples
were placed into CK-14 ceramic beaded tubes containing 500 ll of
TRIzol (Invitrogen) and homogenised with the Precellys 24 (Stret-
ton Scientific) for 2  15 s cycles at 5500 rpm. The samples were
centrifuged at 8000 rpm for 3 min at 4 C and the supernatant
transferred to fresh micro-centrifuge tubes and RNA extracted
according to manufacturer’s instructions (Qiagen). The RNA was
resuspended in 30 ll RNase-free dH2O and stored at 80 C. RNA
concentration was quantified using a NanodropTM.
2.5. Quantitative real-time PCR (QPCR)
cDNA was synthesised from 150 ng RNA and amplified by qPCR
as previously described [30]. The PCR primers used have been
described previously [31]. Data was normalised to a geometric
mean of ribosomal protein large P0 (RPLPO) and b2 microglobulin
using the DDCt method.
Fig. 3. Electroporation increases myostatin and FHL1 expression in vivo. Expression
of myostatin and FHL1 in adult mouse skeletal muscle was determined by qPCR (A
and B). Myostatin expression was elevated 14 days after electroporation with
pCAGGS-myostatin compared to the contralateral TA electroporated with pCAGGS
alone (A). Median FHL1 expression was higher 14 days after electroporation
pCAGGS-FHL1 compared to pCAGGS but this increase did not reach significance
(p = 0.08). There was a significant increase in the FHL1 expression 14 days after
electroporation with both pCAGGS-FHL1 and pCAGGS-myostatin than with
pCAGGS-myostatin alone (B).
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Data are presented as mean ± SEM for data with a parametric
distribution and median (interquartile range) for non-parametric
data. Differences were determined by t-test for parametric data
and by Mann–Whitney test for non-parametric data. To establish
differences in muscle fibre profiles data were compared by one-
way ANOVA for each point. Significance was set at a 2 tailed p
value = 0.05).
3. Results
3.1. Effect of FHL1 on SMAD reporter gene expression in response to
TGFb ligands
Treatment of the cells with 10 ng/mL TGFb alone increased
CAGA12 luciferase reporter gene expression by 4-fold and thiswas increased further to 7-fold by expression of FHL1 (Fig. 1a)
consistent with an effect of FHL1 on TGF-b signalling. FHL1 expres-
sion had no effect on luciferase activity in the absence of added
TGF-b. In the absence of transfection with an FHL1 expression plas-
mid (i.e. in the cells transfected with pCDNA), myostatin had no
effect on luciferase activity at concentrations below 100 ng/mL.
At 100 ng/mL myostatin alone increased luciferase activity 1.4-
fold (p = 0.025). However, in the presence of FHL1, myostatin
caused a detectable increase in luciferase activity at all concentra-
tions above 20 ng/mL (20 ng/mL 1.4-fold, p = 0.003, 50 ng/mL, 1.8-
fold p < 0.001, 100 ng/mL 1.7-fold p = 0.001). Furthermore, at all
doses myostatin caused a larger increase in mean luciferase activ-
ity in the presence of FHL1 than in its absence (Fig. 1b) which
reached statistical significance for 50 ng/mL (20 ng/mL 1.3-fold,
p = 0.065, 50 ng/mL, 1.5-fold p = 0.001, 100 ng/mL 1.2-fold
p = 0.221). These data show that FHL1 increases the activity of
myostatin signalling in myoblasts. The lack of a significant effect
of FHL1 on luciferase activity at 100 ng/mL myostatin raises the
possibility that FHL1 increases the sensitivity of the cell to myo-
statin rather than the size of the response. Alternatively it may
reflect the weakness of the response of the reporter system to myo-
statin compared to TGF-b.
3.2. Effect of FHL1 on myotube diameter in response to myostatin
To determine whether FHL1 enhanced myostatin dependent
myotube wasting, we determined the effect of myostatin on myo-
tube size in the presence or absence of FHL1 expression. Treatment
of the cells with 20 ng/mL myostatin alone did not alter the size of
the myotubes 2 or 4 days after treatment (2 days-myostatin
29.6 lm (24.1, 33.4) Control 30.1 lm (22.8, 36.2, Fig.2a and b),
4 days-myostatin 29.3 lm, (24.9, 37.4) Control 30.4 lm, (25.3,
36.0), Fig. 2), an effect consistent with the lack of CAGA12 activation
seen inmyoblasts at this dose. Transfection of FHL1 into C2C12 cells
caused a small but significant increase in myotube size (FHL1
31.1 lm (25.5, 39.8) compared to control transfection 30.1 lm
(22.8, 36.2) p < 0.05, Fig. 2), consistent with previously described
effects [15]. In contrast to the lack of effect of myostatin on control
cells, in cells expressing FHL1, 20 ng/mLmyostatin caused a signifi-
cant reduction in myotube size both 2 and 4 days after treatment
(2 days-FHL1 31.1 lm (25.5, 39.8 lm), vs FHL1 + myostatin
27.1 lm (23.9, 31.6) p < 0.001, 4 days-(FHL1 31.5 lm, (27.5, 36.2),
FHL1 + myostatin 28.5 lm, (23.9, 31.1) p < 0.001) Fig. 2).
3.3. Effect of FHL1 on myostatin induced muscle wasting in vivo
To determine whether FHL1 also increased myostatin depen-
dent atrophy in vivo, we over-expressed myostatin and FHL1, alone
or in combination in the tibialis anterior (TA) muscles of mice by
electroporation. To determine the effect of myostatin or FHL1
alone, mice were injected in the right TA with pCAGGS-
myostatin (M1) or pCAGGS-FHL1 (F) and in the left TA with empty
pCAGGS as a control (C1 and C2 respectively). To determine the
effect of FHL1 on myostatin activity, mice were electroporated in
the right TA with both pCAGGS-myostatin and pCAGGS-FHL1 (M
+F) and in the left TA with pCAGGS-myostatin (M2). Electropora-
tion with pCAGGS-myostatin increased myostatin mRNA expres-
sion in M1 compared to the contralateral C1 (Fig. 3A). Similarly,
electroporation of pCAGGS-FHL1 increased FHL1 expression in F
and F+M muscles compared to their respective controls (C2 and
M2) but this only reached statistical significance in F+M vs M2
(Fig. 3B). However, there was no effect of myostatin on FHL1
expression and FHL1 mRNA was significantly higher in the F and
F+M groups combined than in all other groups combined (2-fold,
p < 0.01, Fig. 3B). Myostatin expression in the muscle electropo-
rated with both plasmids (F+M) did not differ from that in the
Fig. 4. Effect of myostatin and FHL1 expression on muscle fibre size in vivo. Sections of the tibialis anterior were cut from the same level of each muscle and stained with
haematoxylin and eosin stained sections. Representative sections are shown in (A). Comparison of fibre size in the TAs of individual mice electroporated with (B) right TA
pCAGGS-myostatin (M1) and left TA pCAGGS (C1), (C) right TA pCAGGS-FHL1 (F) and left TA pCAGGS (C2), (D) right TA pCAGGS-myostatin and pCAGGS-FHL1(M+F), left TA
pCAGGS-myostatin (M2). (E) unpaired analysis of fibre diameter in TAs electroporated with control vector (n = 8), myostatin (n = 8), FHL1 and myostatin (F+M, n = 4), FHL1
(n = 4) showed that myostatin reduced fibre size compared to control (p < 0.001), FHL1 increased fibre size compared to control (p < 0.001) but FHL1 + myostatin caused a
larger reduction in fibre diameter than myostatin alone (p < 0.001 FHL1 vs FHL1 + myostatin, p = 0.033 myostatin vs FHL1 + myostatin). ⁄⁄⁄p < 0.001, ⁄p < 0.05.
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(M2) (Table 3).
Sections from each electroporated muscle were stained with
H&E to analyse the effect of electroporation on muscle fibre diam-
eter (Fig 4). Consistent with previous studies, myostatin expression
alone caused a 10% decrease in fibre diameter [32] (Fig. 4A and F,
from 37.8 ± 0.9 lm (n = 8) to 33.1 ± 0.9 lm (n = 8) p < 0.001)
whereas FHL1 expression increased fibre diameter by 10% com-
pared with the control TA (Fig. 4B and F to 42.7 ± 0.5 lm (n = 4)
p < 0.001). Co-expression of FHL1 with myostatin in the same TA
caused a larger decrease in fibre diameter than expression of myo-
statin alone (8.7% further reduction, to 30 ± 1.2 lm (n = 4),
Fig. 4C and F, p = 0.033). Comparing the diameter of myofibres
overexpressing FHL1 in the presence or absence of myostatin
showed that myostatin decreased fibre diameter from
42.7 ± 5 lm to 30 ± 1.2 lm a reduction of approximately 25%
(p < 0.001).
To analyse further the effects on muscle fibre size, we deter-
mined the proportion of fibres within 5 lm bins and the propor-
tion of fibres below a given fibre diameter again in 5 lm steps
(Fig. 5). Comparison of the two sets of control muscles with each
other and the two sets of myostatin muscles with each other,
showed no significant difference at any point, validating the tech-
nique and showing that expression of myostatin or FHL1 in the
contralateral TA did not affect fibre size (Fig. 5E and F). This
approach also allowed us to pool the data from the control and
the data from the myostatin treated muscles. Myostatin caused a
significant shift to smaller fibres compared to control electropo-
rated muscles (Fig. 5A and G). FHL1 caused a significant increase
in the proportion of larger fibres compared to control fibres.
(Fig. 5B, E and G). In FHL1 expressing muscles, myostatin caused
a greater increase in the smallest fibres than myostatin alone with
a significant increase in the fibres below 25 lm (Fig 5C, F and G).Fibre proportionswere analysed by immunofluorescence (Figs. 6
and 7). Comparison of the proportion of fibres in each muscle
showed that myostatin expression reduced the proportion of type
IIB fibres and increased the proportion of IIA fibres compared to the
controls. FHL1 alone did not affect the fibre proportion compared
to controls and in combination with myostatin appeared to cause
an increase in type IIB/type IIX fibres (p = 0.037, Fig. 6).
Gene expression within the groups was then examined to iden-
tify changes in pathways associated with muscle wasting. Given
that myostatin over-expression alone caused wasting, downstream
TGF-b signalling was analysed, revealing a significant increase in
PAI-1 (1.49-fold, M1 compared to C1, p < 0.05, Table 1), suggesting
activation of the TGF-b signalling pathway. To identify the atrophy
pathway induced by the myostatin signalling, expression of com-
ponents of proteasomal degradation, autophagy and apoptosis
were measured. No significant differences were observed in the
expression of any of these genes but there was a trend to a
decrease in expression of ATG4B (0.73-fold, p = 0.059) and ATG12 l
(0.58-fold, p = 0.076), genes that are associated with autophagy.
Changes in the expression of the myosin heavy chains were iden-
tified; with an increase in MHCI (13.1-fold, p < 0.01) and a decrease
in expression of MHCIIB (0.34, p < 0.05, consistent with the
observed reduction in type IIB fibres) and a trend towards a reduc-
tion in MHCIIX (0.64, p = 0.06). There was no apparent increase in
the expression of MHCIIA even though there was an increase in
type IIA fibre proportion possibly due to the small number of sam-
ples analysed. There was also a significant increase in myogenin
expression (1.82, p < 0.05).
Expression of FHL1 alone did not significantly alter the expres-
sion of any of the genes tested (F compared to C2, Table 2). How-
ever, there was a trend to an increase in VEGF-C (1.2-fold,
p = 0.085). Additionally there was a trend to a decrease in BAX
expression (0.81-fold, p = 0.075).
Fig. 5. Effect of FHL1 on myostatin induced reduction in fibre size. Fibre profiles for electroporated muscles produced by determining the number of fibres from 0 to 15 lm,
between 15 and 65 lm in 5 lm in bins and above 65 lm comparing left and right TA in the same animals (A–C) or between muscles expressing FHL1 alone and muscles
expressing FHL1 and myostatin (D). Myostatin expression increased the proportion of small diameter fibres in the TA of mice (M-1 myostatin, C-1 control electroporated TAs
from the same animals, n = 4), A). Electroporation of FHL1 increased the proportion of larger diameter fibres (F, FHL1 expression, C-2 control from the same animals (n = 4), B).
Electroporation of FHL1 and myostatin together caused a greater reduction in fibre diameter than expression of myostatin alone (M+F; myostatin and FHL1 M-2; myostatin
expression in the contralateral TA of the same animals (n = 4), C). Myostatin caused a larger decrease in fibre diameter in TAs expressing FHL1 than in those not expressing
FHL1 (compare D and A). (E and G) Fibre profiles plotted as proportion of fibres below the indicated fibres diameter in 5 lm increments. E, Fibre profiles for pCAGGS
electroporated muscles (C1 and C2) and for the FHL1 expressing muscle (F, the contralateral TA to C2). F. Fibre profiles for myostatin expressing muscles (M1 and M2) and the
FHL1 and myostatin expressing muscle (F+M). ⁄F+M significantly greater that M1 or M2 p < 0.015 ANOVA). G Fibre profiles for all muscles with data from C1 and C2 pooled
(C), M1 and M2 pooled (M). Statistical analysis by ANOVA showed F+M different to M p < 0.001 up to 0–25 lm, M different to C at all points from 30 to 65 lm p < 0.003, C
different to F at all points from 30 to 65 lm. Data are presented as mean ± SEM. In each group, 80–90 randomly selected fibres were measured from 8 to 9 random selected
fields of view from H and E stained TA cross sections.
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compared to M2, Table 3) caused a significant increase in the
expression of genes associated with autophagy (ATG12 l; 1.46-
fold, p < 0.05 with a trend to an increase in ATG4B; 1.41-fold,
p = 0.052) and apoptosis (BAD; 1.36-fold, p < 0.05 and BAX; 1.29-
fold, p < 0.01) as well as a trend to an increase in MuRF1 (1.27-
fold, p = 0.056, Table 3) compared to the expression of myostatin
alone. There were no significant differences in the expression of
myosin heavy chains in between muscles expressing myostatin
alone and myostatin and FHL1 but there was a trend towards an
increase in the expression of MHCIIX (1.88-fold, p = 0.058) and
MHCI (2.99-fold, p = 0.075).
4. Discussion
Our data indicate that exogenous expression of FHL1 increases
myostatin activity in skeletal muscle cells in vitro and exacerbates
muscle wasting in the presence of elevated myostatin in vivo. The
accepted role for FHL1 is as a promoter of hypertrophy, as shown
by the effects of overexpression of FHL1 in mice and postural mus-
cle atrophy in patients with mutations in FHL1 [15,16]. In the
absence of myostatin we observed an increase in both myotube
and myofibre diameter in response to FHL1 consistent with the
prior data. However, in the presence of myostatin we found that
FHL1 enhanced the effects of myostatin both in vitro and in vivo.These data are consistent with FHL1 potentiating the effects of
TGF-b as identified in hepatic carcinoma cells [14]. However, in
muscle cells FHL1 did not increase SMAD signalling in the absence
of a TGF-b ligand as observed by Ding et al. in tumor cells [14]. The
reason for this difference is not clear but differences in cell type
with different relative levels of expression or localisation of CK1d
or SMAD proteins may provide an explanation.
The activation of myostatin by FHL1 may help to explain the
increase in FHL1 following sciatic nerve section [17] and the asso-
ciation of FHL1 with weakness in COPD patients [19] as myostatin
expression increases in both situations [33,34]. Furthermore, FHL1
is expressed at higher levels in type II fibres than in type I fibres
raising the possibility that it contributes to the greater sensitivity
of type II fibres to myostatin.
Myostatin has previously been shown to increase the expres-
sion of the atrogenes MuRF-1 and atrogin-1 and we have previ-
ously shown that myostatin increases the expression of
autophagy-associated genes in vitro [31,35]. Whilst there was no
detectable increase in the expression of genes associated with
these pathways in the muscles treated with myostatin alone in
the presence of both myostatin and FHL1, the expression of genes
associated with autophagy and apoptosis were increased consis-
tent with muscle atrophy. The lack of increase in the presence of
myostatin alone may have been the result of the time point studied
thus any earlier increase in the expression of these genes may have
Fig. 6. Effect of FHL1 and myostatin on fibre proportions in the TA. Sections of TA were analysed by immunofluorescence to determine the effect of FHL1 and myostatin on
fibre proportions. (A) representative staining of a whole TA cross section imaged at 10x and tiled. Red = type IIA/Laminin, no stain = type IIX, green = type IIB blue = type I/
nuclei, scale bar = 500 lm. Region in the square is shown expanded scale bar = 50 lm. (B) individual fluorescent channels for the inset square. Fibre type analysis comparing
(C) control (C1) and myostatin (M1), (D) control (C2 and FHL1 (F) and (E) myostatin (M2) and myostatin + FHL1 (M+F). Statistics show significant differences by paired t-test.
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increases observed in the presence of myostatin and FHL1 where
the atrophy was greater.
4.1. Critique of the experimental approach
The data present a consistent argument that FHL1 increases the
functional effects of myostatin in vitro and in vivo. This observation
is also consistent with activation of SMAD signalling by FHL1 in
other cells. However, there are a number of potential confounding
factors in the data that need to be considered. First it should be
noted that the experimental approach relies on over-expression
and it is possible that this causes an artefact. Against this sugges-
tion is the consistency of the responses in myoblasts, myotubes
and muscle in vivo as FHL1 increases myostatin activity measured
by 3 different assays (luciferase based SMAD reporter assays, myo-
tube wasting in vitro and myofibre wasting in vivo. The second
potential confounding issue is that the in vivo response occurs on
the background of a regeneration response to electroporation
injury complicating any picture. However, our observations on
the effects of the single agents (myostatin and FHL1) are consistentwith previous studies using transgenic over-expression, which
does not cause injury and regeneration [15,36]; with myostatin
alone causing atrophy and FHL1 alone causing hypertrophy. Fur-
thermore, the effects we observe in vitro are the same as those
we observe in vivo (i.e. FHL1 alone increases myotube size whereas
in combination with myostatin it causes a greater reduction in
myotube size than myostatin alone). Together these observations
suggest that the combined response in vivo is not caused by the
experimental approach. The third confounding factor is that we
did not observe large changes in gene expression in response to
either FHL1 or myostatin. Indeed only the increase in myostatin
(which we over expressed) and MCH-I exceeded a 2-fold change
although a number of other changes reached statistical signifi-
cance. These small changes are likely to result from the time-
point chosen for the analysis which is 2 weeks after the electropo-
ration and the likely reduction in the expression of the transfected
genes with time. Such small changes and the fact that many trends
did not reach statistical significance may account for the apparent
opposite direction of change observed for a number of the genes
between myostatin compared to control (Table 1) and myostatin
+ FHL1 compared to myostatin (Table 3). However, as FHL1 also
Fig. 7. Representative images of fibre type staining. Sections of TA were analysed by immunofluorescence to determine the effect of FHL1 and myostatin on fibre proportions.
The pairs of sections shown (A and B, C and D, E and F) are the right TA (top panel) and left TA (bottom panel) from the same animal and were transfected with the A; pCAGGS-
MSTN, B; empty pCAGGS, C; pCAGGS-FHL1, D; empty pCAGGS, E; pCAGGS-FHL1 and pCAGGS-MSTN, F pCAGGS-MSTN. Sections were imaged at 10 and tiled. Red = type IIA/
Laminin, no stain = type IIX, green = type IIB blue = type I/nuclei.
Table 1
Effect of Myostatin expression on muscle gene expression in the TA.
Control (C1) Myostatin
(M1)
Group Gene AV SEM AV SEM p
FHL1 1.00 0.22 0.77 0.14 Ns
myostatin 1.00 0.27 4.86 0.39 **
Myosins MyHC1 1.00 0.28 13.1 4.49 **
MyHC2x 1.00 0.34 0.64 0.15 0.060
MyHC2a 1.00 0.40 1.26 0.46 Ns
MyHC2b 1.00 0.32 0.34 0.09 *
TGF-b signalling VEGF-C 1.00 0.25 0.80 0.14 Ns
PAI-1 1.00 0.29 1.49 0.27 *
Autophagy ATG-4B 1.00 0.19 0.73 0.15 0.059
LC3B 1.00 0.22 0.85 0.20 Ns
ULK-2 1.00 0.27 0.67 0.14 Ns
ATG-12 1.00 0.32 0.58 0.13 0.076
Apoptosis Bad 1.00 0.18 0.92 0.15 Ns
Bax 1.00 0.18 0.84 0.09 Ns
Atrophy Atrogin 1.00 0.16 0.75 0.15 Ns
Murf 1.00 0.21 0.81 0.17 Ns
Myogenesis MyoD 1.00 0.30 1.04 0.21 Ns
Myogenin 1.00 0.24 1.82 0.27 *
Table of fold changes for each gene with expression in the myostatin expressing
muscle (M1) compared to expression in the contralateral controls (C1). Values are
normalised to average of the control TAs (C1) group (n = 4 in each group). Data
represent mean ± SEM, where ⁄p < 0.05, ⁄⁄p < 0.01 from paired t-test of log trans-
formed data.
Table 2
Effect of FHL1 expression on muscle gene expression in the TA.
Control (C2) FHL1 (F)
Group Gene AV SEM AV SEM p
FHL1 1.00 0.51 1.80 0.36 0.083
Myostatin
Myosins MyHC1 1.00 0.59 0.61 0.23 Ns
MyHC2x 1.00 0.44 1.62 0.23 Ns
MyHC2a 1.00 0.60 1.26 0.41 Ns
MyHC2b 1.00 0.48 1.51 0.28 Ns
TGF-b signalling VEGF-C 1.00 0.40 1.20 0.25 Ns
PAI-1 1.00 0.35 0.99 0.13 Ns
Autophagy ATG-4B 1.00 0.37 0.83 0.17 Ns
LC3B 1.00 0.40 0.91 0.20 Ns
ULK-2 1.00 0.38 0.80 0.21 Ns
ATG-12 1.00 0.36 1.16 0.12 Ns
Apoptosis Bad 1.00 0.54 0.79 0.14 Ns
Bax 1.00 0.10 0.81 0.20 0.075
Atrophy Atrogin 1.00 0.43 0.88 0.11 Ns
Murf 1.00 0.37 0.83 0.09 Ns
Myogenesis MyoD 1.00 0.48 0.66 0.12 Ns
Myogenin 1.00 0.27 0.76 0.02 Ns
Table of fold changes for each gene with expression in the FHL1 expressing
muscle (F) compared to expression in the contralateral controls (C2). Values are
normalised to average of control TAs (C2) (n = 4 in each group). Data represent
mean ± SEM.
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Table 3
Effect of FHL1 expression on muscle gene expression in the muscles that express
myostatin.
Myostatin
(M2)
Myostatin
+ FHL1 (M+F)
Group Gene AV SEM AV SEM p
FHL1 1.00 0.25 1.66 0.35 *
Myostatin 1.00 0.09 0.93 0.31 Ns
Myosins MyHC1 1.00 0.56 2.99 1.14 0.075
MyHC2x 1.00 0.09 1.88 0.44 0.058
MyHC2a 1.00 0.25 1.45 0.47 Ns
MyHC2b 1.00 0.29 1.24 0.52 Ns
TGF-b signalling VEGF-C 1.00 0.21 1.23 0.17 Ns
PAI-1 1.00 0.22 1.38 0.54 Ns
Autophagy ATG-4B 1.00 0.25 1.41 0.24 0.052
LC3B 1.00 0.21 1.15 0.27 Ns
ulk-2 1.00 0.31 1.34 0.44 Ns
ATG-12 1.00 0.15 1.46 0.22 *
Apoptosis Bad 1.00 0.15 1.29 0.24 *
Bax 1.00 0.12 1.36 0.20 **
Atrophy Atrogin 1.00 0.20 1.23 0.19 Ns
Murf 1.00 0.17 1.27 0.25 0.056
Myogenesis MyoD 1.00 0.23 1.25 0.22 Ns
Myogenin 1.00 0.31 0.85 0.16 Ns
Table of fold changes for each gene with expression in the myostatin + FHL1 mus-
cles (M+F) expressing muscle compared to expression in the contralateral myo-
statin expressing muscles (M2). Values are normalised to the average of the M2 TAs
(n = 4 in each group). Data represent mean ± SEM, where ⁄p < 0.05, ⁄⁄p < 0.01 from
paired t-test of log transformed data.
J.Y. Lee et al. / FEBS Open Bio 5 (2015) 753–762 761interacts with a number of transcription factors including NFATC1
[15] it is also possible that these differences in direction of change
reflect a different time course that results from the interaction
between FHL1 and myostatin or some other factor within the
experimental system.
5. Conclusion
In conclusion we demonstrate that exogenous FHL1 expression
exacerbates the atrophic effects of myostatin in vitro and in vivo.
These observations together with the relative restriction of FHL1
to type II fibres observed in the literature [16], suggest that FHL1
may contribute to type II fibre atrophy under the appropriate con-
ditions. However, further experiments are required to confirm that
FHL1 contributes to the increased sensitivity of type II fibres to
myostatin dependent atrophy.
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